Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2428-2431

  Pantel, Alix ^a   Petrella, Stéphanie ^b,c,d   Veziris, Nicolas ^a,e,f   Matrat, Stéphanie ^a   Bouige, Aurélie ^a   Ferrand, Hélène ^a   Sougakoff, Wladimir ^a,e,f   Mayer, Claudine ^b,c,d   Aubry, Alexandra ^a,e,f  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT PASTEUR   (France)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLONE DERIVATIVE; RECOMBINANT PROTEIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; GENE REPRESSION; GENETICS; HUMAN; IC50; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MISSENSE MUTATION; MYCOBACTERIUM TUBERCULOSIS; SITE DIRECTED MUTAGENESIS;

ANTITUBERCULAR AGENTS; DNA GYRASE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; RECOMBINANT PROTEINS; SUPPRESSION, GENETIC;

EID: 85017034995     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw169     Document Type: Article

References (20)

1. Gandhi NR, Nunn P, Dheda K et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-43.
2. Bonilla CA, Crossa A, Jave HO et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One 2008; 3: e2957.
3. WHO. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance: Anti-Tuberculosis Drug Resistance in the World, Report No 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008; 1-153.
4. Aubry A, Pan XS, Fisher M et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004; 48: 1281-8.
5. Brossier F, Veziris N, Aubry A et al. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010; 48: 1683-9.
6. Sirgel FA, Warren RM, Streicher EM et al. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67: 1088-93.
7. Von Groll A, Martin A, Jureen P et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009; 53: 4498-500.
8. Cheng AFB, YewWW, Chan EWC et al. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinoloneresistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004; 48: 596-601.
9. Aubry A, Veziris N, Cambau E et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006; 50: 104-12.
10. Brossier F, Sola C, Millot G et al. Comparison of a semiautomated commercial repetitive-sequence-based PCR method with spoligotyping, 24-locus mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing, and restriction fragment length polymorphismbased analysis of IS6110 for Mycobacterium tuberculosis typing. J Clin Microbiol 2014; 52: 4082-6.
11. Malik S, Willby M, Sikes D et al. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012; 7: e39754.
12. Kaswa MK, Aloni M, Nkuku L et al. Pseudo-outbreak of pre-extensively drug-resistant (pre-XDR) tuberculosis in Kinshasa: collateral damage caused by false detection of fluoroquinolone resistance by GenoType MTBDRsl. J Clin Microbiol 2014; 52: 2876-80.
13. Aubry A, Sougakoff W, Bodzongo P et al. First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. PLoS One 2014; 9: e95083.
14. Preisler A, Heisig P. The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G). J Antimicrob Chemother 2009; 63: 290-4.
15. Blanc-Potard AB, Labesse G, Figueroa-Bossi N et al. Mutation at the 'exit gate' of the Salmonella gyrase A subunit suppresses a defect in the gyrase B subunit. J Bacteriol 2005; 187: 6841-4.
16. Heddle JG, Lu T, Zhao X et al. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity. J Mol Biol 2001; 309: 1219-31.
17. Umubyeyi AN, Rigouts L, Shamputa IC et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother 2007; 59: 1031-3.
18. Mitarai S, Kafwafbulula M, Terunua H et al. Mycobacterium tuberculosis and gyrA variation in Zambia. Trop Med Heal 2005; 33: 91-4.
19. Wohlkonig A, Chan PF, Fosberry AP et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 2010; 17: 1152-3.
20. Aldred KJ, McPherson SA, Turnbough CL et al. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res 2013; 41: 4628-39.